Integrity Coronary Stent System    

Log In

Forgot Your Password?

Not a member? Click here!

Merit Medical’s One Snare System Cleared by FDA
TeraRecon Announces AnyOne Upgrade Program
First Patients Enrolled in Trial of Reva Medical’s Fantom Bioresorbable Scaffold
ArtVentive Introduces EOS Device in the United States
Time to Treatment (and Transport) Issues: Selection of Reperfusion Modality, and Primary Angioplasty with No On-Site Surgery



Total Abstinence From Thrombectomy?

The benefits of routine thrombectomy in patients undergoing PPCI has been controversial. The TOTAL study, a randomized study of 5033 patients undergoing PPCI alone or PPCI plus thrombectomy, has indicated that the technique did not reduce the risk of CV death, recurrent MI, cardiogenic shock or heart failure. Thrombectomy was associated with an increased risk of stroke within 3 days.

For more, click here




Matrix Adds to the Bivalirudin Controversy

The clinical benefits of bivalirudin in patients undergoing PCI has recently been questioned. The MATRIX study, a randomized study of 7209 ACS patients, has indicated that bivalirudin did not reduce the risk of MACE or net adverse clinical events. Bivalirudin did however reduce all-cause mortality bleeding measures.

For more, click here





The DAPT Duration Debate Set to Continue

The optimal duration of dual antiplatelet therapy following coronary stenting with DES has recently been the subject of intense debate. The latest meta-analysis, comparing strategies of short (≤ 6 months) and long-term (≥1 year) DAPT therapy, has indicated that short and long-term therapy are associated with similar MACE rates whereas short-term therapy is associated with lower rates of bleeding.

For more, click here




Adverse Effects of Smoking Post Revascularization

Smoking may be associated with a paradoxical beneficial effect in patients with established CAD. Five-year follow-up data from the landmark SYNTAX study has indicated that as compared to non-smokers, smokers had higher incidence of recurrent MI in both revascularization arms. Smoking was also identified as an independent predictor of death, MI or stroke.

For more, click here



Strokes in TAVR Is it a Deal Breaker?
- Samir Kapadia, MD
CoreValve US Pivotal Trial
- John V. Conte, MD
Myocardial infarction with no obstructive coronary atherosclerosis
- Giampaolo Niccoli, MD, PhD
Incidence, Predictors, and Prognostic Impact of Late Bleeding (≥30 days) Complications after Transcatheter Aortic Valve Replacement (TAVR)
- Philippe Généreux, MD
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD
 Click here to visit the WEBEX archives

Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic AdultsThe BioImage Study.
U Baber, et al.
JACC 2015; 65:1065-1074
Discordance Between Echocardiography and MRI in the Assessment of Mitral Regurgitation SeverityA Prospective Multicenter Trial.
S Uretsky, et al.
JACC 2015; 65:1078-1088
Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent ImplantationAn Individual Patient Data Pairwise and Network Meta-Analysis.
T Palmerini, et al.
JACC 2015; 65:1092-1102
Smoking Is Associated With Adverse Clinical Outcomes in Patients Undergoing Revascularization With PCI or CABGThe SYNTAX Trial at 5-Year Follow-Up.
Y Zhang, et al.
JACC 2015; 65:1107-1115
Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary StentsThe Dual Antiplatelet Therapy Randomized Clinical Trial.
D Kereiakes, et al.
JAMA 2015; 313:1113-1121
Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial InfarctionThe BRIGHT Randomized Clinical Trial.
Y Han, et al.
JAMA 2015 Online
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis.
K Chan, et al.
Circ 2015; 131:972-979
Temporal Trends in the Incidence and Prognosis of Aortic Stenosis: A Nationwide Study of the Swedish Population.
A Martinsson, et al.
Circ 2015; 131:988-994
Relation Between Door-to-Balloon Times and Mortality After Primary Percutaneous Coronary Intervention Over Time: A Retrospective Study.
B Nallamothu, et al.
The Lancet 2015; 385:1114-1122
Comparison of Plaque Characteristics in Narrowings With ST-Elevation Myocardial Infarction (STEMI), Non-STEMI/Unstable Angina Pectoris and Stable Coronary Artery Disease (from the ADAPT-DES IVUS Substudy).
L Dong, et al.
AJC 2015; 115:860-866
Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
J Yeboah, et al.
AHJ 2015; 169:387-395

Poll Archives
CoreValve US Pivotal Trial - Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting
John V. Conte, M.D.
Alexandra Lansky, M.D.
The REGULATE-PCI Randomized Clinical Trial
Roxana Mehran, M.D.
Marc S. Sabatine, M.D., M.P.H.
Promise Trial
Pamela S. Douglas, M.D.
CoreValve US Pivotal Trial - 2-Year Outcomes
Michael J Reardon, M.D., F.A.C.C.
Sanjit Jolly, M.D.
Rajeev K. Pathak, M.D.
(PROMISE) Trial: Economic Outcomes
Daniel B. Mark, M.D., M.P.H.
Drug-Resistant Hypertension in an Asian Population
Byeong-Keuk Kim, M.D.
Reduced Blood Pressure Lowering Effect of Catheter-Based Renal Denervation in Patients with Isolated Systolic Hypertension: Data from Pooled SYMPLICITY HTN Trials
Felix Mahfoud, M.D.
BEST Trial
Seung-Jung Park, M.D., PhD
Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
Paul Sorajja, M.D.
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Susheel Kodali, M.D.
M. Valgimigli, M.D., PhD
C. Michael Gibson, M.S., M.D.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial
Michael J. Mack, M.D.
Relation Between Frailty and Outcomes After Transcatheter Aortic Valve Replacement
Philip Green, M.D.
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Marc S. Sabatine, M.D., M.P.H.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD


Infraredx Launches Advanced TVC Imaging System and TVC Muller Extended Bandwidth NIRS-IVUS Catheter

Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting Stent in United States

Toshiba’s Infinix 4DCT Receives FDA Clearance with Aquilion PRIME CT Configuration

Boston Scientific Announces Definitive Agreement To Acquire American Medical Systems' Urology Portfolio For Up To $1.65 Billion

Penumbra Launches POD Embolization Anchoring Device at SIR

Boston Scientific to Acquire American Medical Systems’ Urology Portfolio

ArtVentive Introduces EOS Device in the United States

Vascutek to Distribute Vascular Flow Technologies’ Spiral Flow Grafts in Europe

Cardinal Health to Acquire Cordis

FDA Approves Medtronic’s In.Pact Admiral DCB to Treat SFA and Popliteal Artery Disease

Teleflex Awarded Dialysis Agreement With Premier

ArtVentive Medical’s EOS Device Receives FDA Clearance

Merit Medical’s One Snare System Cleared by FDA

FDA Clears ReFlow Medical’s Spex Shapeable Support Catheter

Philips to Acquire Volcano

TeraRecon Announces AnyOne Upgrade Program

CSI Completes COAST Enrollment in Japan

FDA Clears HeartFlow’s FFRCT Technology

Enrollment Begins for Neovasc’s TIARA-I Clinical Trial

BIOHELIX-I Trial Enrollment Completed for Biotronik’s Pro-Kinetic Energy BMS

First-in-Human Procedures Performed With the Tendyne TMVI System

First Patients Enrolled in Trial of Reva Medical’s Fantom Bioresorbable Scaffold
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2015 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb